Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients
NCT ID: NCT01305317
Last Updated: 2011-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
74 participants
INTERVENTIONAL
2007-01-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the IgA Repertoire During IgA Deposition Nephropathy.
NCT04092491
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906
Immune System Related Kidney Disease
NCT00001979
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
NCT02526966
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
NCT05791162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lipitor
atorvastatin 20mg daily
Lipitor
Atorvastatin 20mg daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipitor
Atorvastatin 20mg daily for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Accepting to participate in the study
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hormozgan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hormozgan University of Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hamidreza Mahboobi
Role: PRINCIPAL_INVESTIGATOR
Hormozgan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shahid Mohammadi hospital
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
statins and Immunoglobulins
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.